Phreesia, Inc. — Form 10-Q Summary
Reporting period: Three months ended April 30, 2023 (fiscal first quarter of 2024). Unless otherwise noted, financial amounts are in U.S. dollars.
Business context
Phreesia provides healthcare software for patient access, registration and payments, and patient communications for life sciences, payer and other organizations. Revenue comes from subscriptions and related services, payment processing, and network solutions.
Financial performance and liquidity
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Total revenue | $83.8 million | $63.4 million | +32% |
| Operating loss | $37.9 million | $50.6 million | Loss narrowed |
| Net loss | $37.5 million | $51.2 million | Loss narrowed |
| Adjusted EBITDA (non-GAAP) | $(13.8) million | $(30.6) million | Improved |
| Operating cash flow | $(13.7) million | $(33.6) million | Cash use reduced |
| Free cash flow (non-GAAP) | $(19.7) million | $(40.7) million | Cash use reduced |
Approximate calculated margins: operating margin was -45% versus -80%; net margin was -45% versus -81%; Adjusted EBITDA margin was -16% versus -48%. The company remained loss-making.
Revenue by category: subscription and related services $37.9 million (+30%); payment processing fees $24.3 million (+25%); network solutions $21.7 million (+46%). Management attributed subscription growth mainly to new and expanding clients, payment revenue growth to more clients and patient payment activity, and network solutions growth to more and deeper patient outreach programs.
Average healthcare services clients increased to 3,309 from 2,526. Healthcare services revenue per client declined 2% to $18,779, which the company attributed mainly to client growth outpacing payment volume and to the mix of solutions adopted by newer clients. Total revenue per client rose 1% to $25,338. Patient payment volume increased to $1.016 billion from $837 million; payment facilitator volume was 82% versus 80%.
Cash and cash equivalents were $149.8 million at April 30, down $26.9 million from January 31. Net cash used in investing activities was $6.1 million, including $4.7 million of capitalized internal-use software and $1.3 million of property and equipment purchases. Financing activities used $7.2 million, largely for tax withholding on stock awards and finance lease payments.
Total finance lease liabilities and other debt were $13.7 million, up from $7.9 million at January 31, primarily reflecting new finance leases. No borrowings were outstanding under the $100 million SVB revolving facility; availability was subject to facility covenants and cash-location requirements. The company reported compliance with facility covenants at quarter-end.
Material changes and management commentary
- Revenue growth was accompanied by a narrower net loss and lower operating and free cash use year over year. Research and development expense rose 28% to $26.5 million, while sales and marketing expense fell 7% to $37.4 million; general and administrative expense fell 5% to $19.9 million.
- Management said existing cash and cash generated in the normal course of business should fund operations for at least the next 12 months, while also noting that losses and negative cash flows are expected to continue for at least the next year. The filing does not provide specific revenue, earnings or cash-flow guidance.
- Following SVB’s closure, the company transferred a substantial portion of its cash to other financial institutions and said all cash remained available. SVB consented to cash held outside SVB up to $165 million, with an extension through September 15, 2023, conditional on maintaining at least $17 million at SVB. The filing says borrowing under the revolver depends on complying with the cash covenant and other facility covenants.
- Management described the macroeconomic and geopolitical outlook as uncertain, citing inflation, higher interest rates, economic slowdown, financial-market volatility and the Russia-Ukraine conflict. It said these factors had not individually materially affected the business to date, but future effects are difficult to predict.
- Key risks include ongoing losses and uncertain path to profitability; competition, including from EHR and practice-management vendors; client retention and implementation costs; cybersecurity, privacy and healthcare regulatory compliance; reliance on third-party vendors and payment processors; and funding and banking liquidity risks. The company reported no legal proceedings it believed would have a material adverse effect.
Important facts for investors to verify
- Whether revenue growth can continue while reducing operating losses, Adjusted EBITDA losses and negative free cash flow.
- Whether the decline in healthcare services revenue per client persists, and how client growth translates into payment volume and monetization.
- Cash burn and the adequacy of $149.8 million in cash, including the conditional SVB cash-location consent and actual availability of the $100 million facility.
- The increase in finance lease liabilities and the effect of lease and technology infrastructure commitments on future cash requirements.
- Execution and cost of growth, client retention, privacy and security controls, and dependence on third-party processors, vendors and integrations.